Evicenter
MarkdownMedical informationP&T meetings
Lorundrostat (MLS-101)

Hypertension, in combination with other antihypertensive drugs

Also known as MT-4129
Launch
Not announced
Last updated
198 sources

Clinical evidence

Launch-HTN

98 evidence topics · 20 sources

Objective
Location and study date
Study locations by country in the ClinicalTrials.gov record
CountryLocations listed in the record
United States“Alabama Locations”; “Arizona Locations”; “California Locations”; “Connecticut Locations”; “Florida Locations”; “Georgia Locations”; “Idaho Locations”; “Illinois Locations”; “Indiana Locations”; “Kentucky Locations”; “Louisiana Locations”; “Massachusetts Locations”; “Mississippi Locations”; “Missouri Locations”; “Nebraska Locations”; “Nevada Locations”; “New York Locations”; “North Carolina Locations”; “Ohio Locations”; “Oklahoma Locations”; “Pennsylvania Locations”; “Tennessee Locations”; “Texas Locations”; “Utah Locations”; “Virginia Locations”
Australia“Heidelberg Heights, Australia”; “St Albans, Australia”; “Castle Hill, New South Wales, Australia”; “Gosford, New South Wales, Australia”; “Waratah, New South Wales, Australia”; “Sippy Downs, Queensland, Australia”; “Southport, Queensland, Australia”; “Taringa, Queensland, Australia”; “Adelaide, South Australia, Australia”; “Hobart, Tasmania, Australia”; “Perth, Western Australia, Australia”
Bulgaria“Gabrovo, Bulgaria”; “Pleven, Bulgaria”; “Sofia, Bulgaria”; “Stara Zagora, Bulgaria”; “Veliko Tarnovo, Bulgaria”
Canada“Edmonton, Alberta, Canada”; “East York, Ontario, Canada”; “Montreal, Quebec, Canada”
France“Annecy, France”; “Bordeaux, France”; “Nîmes, France”; “Saint-Priest-en-Jarez, France”; “Strasbourg, France”
Germany“Berlin, Germany”; “Deggingen, Germany”; “Karlsruhe, Germany”; “Leipzig, Germany”; “Wiesbaden, Germany”; “Hanover, Lower Saxony, Germany”; “Mainz, Rhineland-Palatinate, Germany”; “Dresden, Saxony, Germany”; “Leipzig, Saxony, Germany”
Italy“Ancona, Italy”; “Bologna, Italy”; “Brescia, Italy”; “Ferrara, Italy”; “Genova, Italy”; “L’Aquila, Italy”; “Messina, Italy”; “Milan, Italy”; “Modena, Italy”; “Naples, Italy”; “Pavia, Italy”; “Pisa, Italy”; “Rome, Italy”; “Rozzano, Milan, Italy”; “Roma, Rome, Italy”
Netherlands“Utrecht, Netherlands”; “Nijmegen, Gelderland, Netherlands”; “Amsterdam, North Holland, Netherlands”; “Dordrecht, South Holland, Netherlands”
Poland“Katowice, Poland”; “Lodz, Poland”; “Olsztyn, Poland”; “Krakow, Lesser Poland Voivodeship, Poland”; “Lubin, Polska, Poland”; “Skierniewice, Polska, Poland”; “Warsaw, Polska, Poland”; “Olsztyn, Warmian-Masurian Voivodeship, Poland”
Puerto Rico“San Juan, Puerto Rico”
Romania“Brasov, Romania”; “Bucharest, Romania”; “Cluj-Napoca, Romania”; “Craiova, Romania”; “Oradea, Romania”; “Timișoara, Romania”; “Târgu Mureş, Mureș County, Romania”; “Timișoara, Timiș County, Romania”
Spain“Badajoz, Spain”; “Barcelona, Spain”; “Córdoba, Spain”; “Granada, Spain”; “Madrid, Spain”; “Santiago de Compostela, Spain”; “Valencia, Spain”
United Kingdom“Aberdeen, United Kingdom”; “Birmingham, United Kingdom”; “Canterbury, United Kingdom”; “Carshalton, United Kingdom”; “Chippenham, United Kingdom”; “Glasgow, United Kingdom”; “Newquay, United Kingdom”; “Sheffield, United Kingdom”; “Stockton-on-Tees, United Kingdom”; “Fowey, Great Britain, United Kingdom”; “London, Great Britain, United Kingdom”; “Plymouth, Great Britain, United Kingdom”; “Torpoint, Great Britain, United Kingdom”; “Canterbury, Kent, United Kingdom”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using change in automated office systolic blood pressure as the primary endpoint
Blood pressure in the FDA table of surrogate endpoints
Disease or usePatient populationSurrogate endpointType of approval appropriate for
“Hypertension”“Patients with hypertension”“Blood pressure”“Traditional”
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Baseline characteristics by randomized group
CharacteristicLorundrostat 50 mg then 100 mg (n = 270)Lorundrostat 50 mg (n = 541)Placebo (n = 272)
Age, mean (SD), y“61.4 (10.3)”View highlighted excerpt for this quote“61.7 (10.6)”View highlighted excerpt for this quote“61.8 (10.4)”View highlighted excerpt for this quote
Male, No. (%)“142 (52.6)”View highlighted excerpt for this quote“294 (54.3)”View highlighted excerpt for this quote“139 (51.1)”View highlighted excerpt for this quote
Female, No. (%)“128 (47.4)”View highlighted excerpt for this quote“247 (45.7)”View highlighted excerpt for this quote“133 (48.9)”View highlighted excerpt for this quote
Asian, No. (%) (lorundrostat n = 267 and n = 535)“4 (1.5)”View highlighted excerpt for this quote“14 (2.6)”View highlighted excerpt for this quote“6 (2.2)”View highlighted excerpt for this quote
Black or African American, No. (%) (lorundrostat n = 267 and n = 535)“72 (26.7)”View highlighted excerpt for this quote“152 (28.1)”View highlighted excerpt for this quote“87 (32.0)”View highlighted excerpt for this quote
White, No. (%) (lorundrostat n = 267 and n = 535)“190 (70.4)”View highlighted excerpt for this quote“366 (67.7)”View highlighted excerpt for this quote“177 (65.1)”View highlighted excerpt for this quote
Hispanic or Latino ethnicity, No. (%)“102 (37.8)”View highlighted excerpt for this quote“191 (35.3)”View highlighted excerpt for this quote“101 (37.1)”View highlighted excerpt for this quote
Body mass index, mean (SD)“32.8 (6.7)”View highlighted excerpt for this quote“33.0 (6.9)”View highlighted excerpt for this quote“32.6 (7.4)”View highlighted excerpt for this quote
Body mass index ≥30 (obesity), No. (%)“166 (61.5)”View highlighted excerpt for this quote“351 (64.9)”View highlighted excerpt for this quote“168 (61.8)”View highlighted excerpt for this quote
eGFR at randomization, mean (SD), mL/min/1.73 m2“92.8 (17.6)”View highlighted excerpt for this quote“90.1 (17.8)”View highlighted excerpt for this quote“91.2 (16.4)”View highlighted excerpt for this quote
eGFR ≥60 mL/min/1.73 m2, No. (%)“255 (94.4)”View highlighted excerpt for this quote“500 (92.9)”View highlighted excerpt for this quote“260 (96.3)”View highlighted excerpt for this quote
Diabetes, No. (%)“76 (28.2)”View highlighted excerpt for this quote“173 (32.2)”View highlighted excerpt for this quote“89 (33.0)”View highlighted excerpt for this quote
Taking 2 antihypertensive medications, No. (%)“106 (39.3)”View highlighted excerpt for this quote“213 (39.4)”View highlighted excerpt for this quote“113 (41.5)”View highlighted excerpt for this quote
Taking ≥3 antihypertensive medications, No. (%)“164 (60.7)”View highlighted excerpt for this quote“328 (60.6)”View highlighted excerpt for this quote“159 (58.5)”View highlighted excerpt for this quote
Thiazide or thiazide-like diuretic, No. (%)“259 (95.9)”View highlighted excerpt for this quote“520 (96.1)”View highlighted excerpt for this quote“259 (95.2)”View highlighted excerpt for this quote
ACE inhibitor or ARB, No. (%)“237 (87.8)”View highlighted excerpt for this quote“467 (86.3)”View highlighted excerpt for this quote“225 (82.7)”View highlighted excerpt for this quote
Calcium channel blocker, No. (%)“140 (51.9)”View highlighted excerpt for this quote“278 (51.4)”View highlighted excerpt for this quote“135 (49.6)”View highlighted excerpt for this quote
Glucagon-like peptide-1 receptor agonists, No. (%)“13 (4.8)”View highlighted excerpt for this quote“30 (5.6)”View highlighted excerpt for this quote“9 (3.3)”View highlighted excerpt for this quote
Sodium-glucose cotransporter 2 inhibitors, No. (%)“14 (5.2)”View highlighted excerpt for this quote“21 (3.9)”View highlighted excerpt for this quote“13 (4.8)”View highlighted excerpt for this quote
Systolic blood pressure, mean (SD), mm Hg“146.6 (11.1)”View highlighted excerpt for this quote“149.0 (12.2)”View highlighted excerpt for this quote“148.8 (12.2)”View highlighted excerpt for this quote
Systolic blood pressure <140 mm Hg, No. (%)“83 (30.7)”View highlighted excerpt for this quote“137 (25.3)”View highlighted excerpt for this quote“73 (26.8)”View highlighted excerpt for this quote
Systolic blood pressure 140 to <160 mm Hg, No. (%)“152 (56.3)”View highlighted excerpt for this quote“294 (54.3)”View highlighted excerpt for this quote“144 (52.9)”View highlighted excerpt for this quote
Systolic blood pressure ≥160 mm Hg, No. (%)“35 (13.0)”View highlighted excerpt for this quote“110 (20.3)”View highlighted excerpt for this quote“55 (20.2)”View highlighted excerpt for this quote
Diastolic blood pressure, mean (SD), mm Hg“86.3 (9.2)”View highlighted excerpt for this quote“87.8 (9.0)”View highlighted excerpt for this quote“87.1 (9.1)”View highlighted excerpt for this quote
Efficacy results
Primary, secondary, and prespecified exploratory blood pressure outcomes
OutcomeLorundrostat baseline, mean (SD)Lorundrostat follow-up, mean (SD)Lorundrostat least-squares mean change (95% CI)Placebo baseline, mean (SD)Placebo follow-up, mean (SD)Placebo least-squares mean change (95% CI)Least-squares mean difference (95% CI)P value
Primary: systolic BP, baseline to 6 wk (pooled lorundrostat n = 808; placebo n = 270)“148.2 (11.9)”View highlighted excerpt for this quote“133.6 (15.3)”View highlighted excerpt for this quote“−16.9 (−19.0 to −14.9)”View highlighted excerpt for this quote“148.6 (12.1)”View highlighted excerpt for this quote“140.7 (15.0)”View highlighted excerpt for this quote“−7.9 (−11.5 to −4.2)”View highlighted excerpt for this quote“−9.1 (−13.3 to −4.9)”View highlighted excerpt for this quote“<.001”View highlighted excerpt for this quote
Secondary: systolic BP <130 mm Hg at 6 wk, No. (%); difference as odds ratio (95% CI)“20 (2.5)”View highlighted excerpt for this quote“356 (44.1)”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“65 (24.1)”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“3.4 (1.5 to 7.8)”View highlighted excerpt for this quote“.003”View highlighted excerpt for this quote
Secondary: taking 2 antihypertensive drugs, 6 wk (lorundrostat n = 318; placebo n = 112; 97.5% CI where reported)“147.6 (11.5)”View highlighted excerpt for this quote“134.2 (14.9)”View highlighted excerpt for this quote“−16.1 (−19.1 to −13.0)”View highlighted excerpt for this quote“148.0 (11.3)”View highlighted excerpt for this quote“141.4 (14.4)”View highlighted excerpt for this quote“−7.2 (−11.7 to −2.8)”View highlighted excerpt for this quote“−8.8 (−14.8 to −2.9)”View highlighted excerpt for this quote“<.001”View highlighted excerpt for this quote
Secondary: taking ≥3 antihypertensive drugs, 6 wk (lorundrostat n = 490; placebo n = 158; 97.5% CI)“148.6 (12.1)”View highlighted excerpt for this quote“133.2 (15.6)”View highlighted excerpt for this quote“−17.2 (−19.6 to −14.7)”View highlighted excerpt for this quote“149.0 (12.6)”View highlighted excerpt for this quote“140.4 (15.5)”View highlighted excerpt for this quote“−8.1 (−12.4 to −3.8)”View highlighted excerpt for this quote“−9.0 (−14.0 to −4.1)”View highlighted excerpt for this quote“<.001”View highlighted excerpt for this quote
Secondary: systolic BP, baseline to 12 wk, escalated dose group (lorundrostat n = 270)“146.6 (11.1)”View highlighted excerpt for this quote“131.9 (14.3)”View highlighted excerpt for this quote“−15.7 (−19.3 to −12.2)”View highlighted excerpt for this quote“148.6 (12.1)”View highlighted excerpt for this quote“141.2 (15.4)”View highlighted excerpt for this quote“−7.3 (−11.1 to −3.5)”View highlighted excerpt for this quote“−8.4 (−13.6 to −3.2)”View highlighted excerpt for this quote“.002”View highlighted excerpt for this quote
Secondary: within-participant analysis, 12 wk (n = 92; 97.5% CI)“148.3 (12.4)”View highlighted excerpt for this quote“138.1 (14.8)”View highlighted excerpt for this quote“−10.2 (−14.3 to −6.1)”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“NA”View highlighted excerpt for this quote“<.001”View highlighted excerpt for this quote
Exploratory: diastolic BP, baseline to 6 wk“87.3 (9.1)”View highlighted excerpt for this quote“79.9 (10.4)”View highlighted excerpt for this quote“−8.6 (−9.9 to −7.3)”View highlighted excerpt for this quote“87.1 (9.0)”View highlighted excerpt for this quote“83.2 (10.1)”View highlighted excerpt for this quote“−5.2 (−7.4 to −3.0)”View highlighted excerpt for this quote“−3.4 (−5.9 to −0.8)”View highlighted excerpt for this quote“.01”View highlighted excerpt for this quote
Exploratory: systolic BP, baseline to 12 wk, 50 mg group (lorundrostat n = 538)“149.1 (12.2)”View highlighted excerpt for this quote“132.5 (16.0)”View highlighted excerpt for this quote“−19.0 (−21.6 to −16.3)”View highlighted excerpt for this quote“148.6 (12.1)”View highlighted excerpt for this quote“141.2 (15.4)”View highlighted excerpt for this quote“−7.3 (−11.1 to −3.5)”View highlighted excerpt for this quote“−11.6 (−16.3 to −7.0)”View highlighted excerpt for this quote“<.001”View highlighted excerpt for this quote
Sensitivity analyses of the primary endpoint
AnalysisLorundrostat LS mean (SE)Placebo LS mean (SE)LS mean difference (SE)95% CI of LS mean differenceP value
Sensitivity analysis 1: intercurrent events treated as missing at random (lorundrostat n = 808; placebo n = 270)“-16.9 (1.1)”“-7.9 (1.9)”“-9.1 (2.1)”“-13.3 to -4.9”“<0.001”
Sensitivity analysis 2: all missing data treated as missing not at random (lorundrostat n = 808; placebo n = 270)“-16.5 (1.1)”“-7.9 (1.9)”“-8.6 (2.2)”“-12.2 to -4.4”“<0.001”
Sensitivity analysis 4: observed data only (lorundrostat n = 755; placebo n = 257)“-17.0 (1.1)”“-7.9 (1.9)”“-9.1 (2.1)”“-13.3 to -4.9”“<0.001”
Participants with and without chronic kidney disease: results by stage
CKD stage (placebo N; lorundrostat 50 mg N)Placebo AOSBP LSM (95% CI) change at week 12Lorundrostat 50 mg AOSBP LSM (95% CI) change at week 12Placebo adjusted (95% CI)Placebo week 12 % with AOSBP <130 mmHgLorundrostat 50 mg week 12 % with AOSBP <130 mmHg
No CKD (202; 406)“-7.2 (-11.3, -3.2)”“-19.4 (-22.2, -16.6)”“-12.2 (-17.1, -7.3)”“22.1”“48.0”
Stage 1 (30; 58)“-8.9 (-15.4, -2.3)”“-19.5 (-24.1, -14.9)”“-10.6 (-18.6, -2.6)”“18.4”“50.6”
Stage 2 (25; 31)“-9.1 (-15.9, -2.4)”“-16.7 (-22.6, -10.8)”“-7.6 (-16.5, 1.4)”“12.0”“28.4”
Stage 3 (10; 38)“-8.5 (-18.1, 1.1)”“-18.5 (-24.1, -13.0)”“-10.1 (-21.1, 1.0)”“30.0”“47.0”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Adverse events by randomized group
Event, No. (%)Lorundrostat 50 mg then 100 mg (n = 270)Lorundrostat 50 mg (n = 538)Placebo (n = 270)
Died“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (0.4)”View highlighted excerpt for this quote
Serious adverse event“2 (0.7)”View highlighted excerpt for this quote“12 (2.2)”View highlighted excerpt for this quote“8 (3.0)”View highlighted excerpt for this quote
Treatment-emergent adverse event, severe“6 (2.2)”View highlighted excerpt for this quote“9 (1.7)”View highlighted excerpt for this quote“8 (3.0)”View highlighted excerpt for this quote
Treatment-emergent adverse event, moderate“30 (11.1)”View highlighted excerpt for this quote“100 (18.6)”View highlighted excerpt for this quote“31 (11.5)”View highlighted excerpt for this quote
Treatment-emergent adverse event, mild“115 (42.6)”View highlighted excerpt for this quote“180 (33.5)”View highlighted excerpt for this quote“59 (21.9)”View highlighted excerpt for this quote
Special interest: severely elevated blood pressure“2 (0.7)”View highlighted excerpt for this quote“10 (1.9)”View highlighted excerpt for this quote“11 (4.1)”View highlighted excerpt for this quote
Special interest: hypotension with symptoms“5 (1.9)”View highlighted excerpt for this quote“11 (2.0)”View highlighted excerpt for this quote“1 (0.4)”View highlighted excerpt for this quote
Special interest: hyperkalemia“7 (2.6)”View highlighted excerpt for this quote“11 (2.0)”View highlighted excerpt for this quote“1 (0.4)”View highlighted excerpt for this quote
Special interest: hyponatremia“28 (10.4)”View highlighted excerpt for this quote“37 (6.9)”View highlighted excerpt for this quote“9 (3.3)”View highlighted excerpt for this quote
Special interest: glucocorticoid deficiency“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“3 (1.1)”View highlighted excerpt for this quote
Special interest: reduction in estimated glomerular filtration rate“9 (3.3)”View highlighted excerpt for this quote“16 (3.0)”View highlighted excerpt for this quote“2 (0.7)”View highlighted excerpt for this quote
Serum sodium and potassium thresholds by randomized group
Level, n (%)Lorundrostat 50 to 100 mg daily (n=270)Lorundrostat 50 mg (n=538)Placebo (n=270)
Serum sodium <132 mmol/L“22 (8.1)”“38 (7.1)”“13 (4.8)”
Serum sodium <130 mmol/L“11 (4.1)”“14 (2.6)”“4 (1.5)”
Serum sodium <125 mmol/L“4 (1.5)”“4 (0.7)”“1 (0.4)”
Serum potassium 5.6 to 6.0 mmol/L, single value“29 (10.7)”“38 (7.1)”“3 (1.1)”
Serum potassium 6.1 to 6.5 mmol/L, single value“2 (0.7)”“5 (0.9)”“1 (0.4)”
Serum potassium >6.5 mmol/L, single value“2 (0.7)”“1 (0.2)”“1 (0.4)”
Serum potassium 5.6 to 6.0 mmol/L, confirmed“24 (8.9)”“31 (5.8)”“2 (0.7)”
Serum potassium 6.1 to 6.5 mmol/L, confirmed“2 (0.7)”“3 (0.6)”“1 (0.4)”
Serum potassium >6.5 mmol/L, confirmed“1 (0.4)”“0”“0”
Study limitations
Summary: study limitations

Launch-HTN randomized 1,083 participants and compared lorundrostat with placebo for 12 weeks, a duration the investigators describe as “consistent with US Food and Drug Administration guidance limiting placebo-controlled studies of antihypertensive medications for this duration”. Longer-term data come from the open-label extension, which enrolled 632 of the 808 participants who received lorundrostat in Launch-HTN. The trial had no active comparator. The primary endpoint, unattended automated office systolic blood pressure at week 6, was chosen “to reflect usual clinical practice”; the investigators note that ambulatory measurement “is the gold standard for assessment of BP”. FDA guidance attributes the cardiovascular benefits of antihypertensive drugs largely to the decrease in blood pressure, and the trial did not measure cardiovascular outcomes.

In the escalation group, 92 of 270 participants (34.1%) met the week 6 criteria and received 100 mg, and the investigators conclude that the higher dose “provided no additional benefit” to participants who had not reached goal on 50 mg; the week 12 placebo-adjusted difference in the escalation group (−8.4 mm Hg) was smaller than in the 50 mg group (−11.6 mm Hg). Two week 12 values are reported for the 50 mg group: −11.6 mm Hg in the publication and 11.7 mm Hg in the March 2025 topline announcement.

Eligibility excluded people with eGFR below 45 mL/min/1.73 m2, serum potassium above 5.0 mmol/L at screening or above 4.8 mmol/L at randomization, serum sodium below 135 mmol/L, or heart failure, myocardial infarction, stroke, or transient ischemic attack within 6 months, and prohibited mineralocorticoid receptor antagonists, epithelial sodium channel inhibitors, and potassium-sparing diuretics. Of the 1,083 participants, 685 (63.3%) had obesity and 432 (39.9%) were taking 2 antihypertensive medications, so the population includes people who would not meet the 2025 AHA/ACC definition of resistant hypertension. Three participants were randomized in Canada. The publication reports 159 sites in 13 countries, while the registry lists 184 locations. Hyperkalemia rates depend on the definition: a single serum potassium above 6.0 mmol/L occurred in 1.5% and 1.1% of the two lorundrostat groups and 0.7% of the placebo group, while the company reports confirmed hyperkalemia of 1.1% and 0.6%, respectively. The responder analysis is described as a “secondary analysis” and the chronic kidney disease analysis as a “Post hoc analysis”; both are published as conference abstracts. No health-related quality of life or patient-reported outcome was reported. The sponsor's chief medical officer and lead statistician are listed among the sponsor leadership of the trial and are authors of the publication.